Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Patricia Industries' subsidiary Advanced Instruments to acquire and merge with…
"Combining these two great companies aligns with our core strategy to develop and commercialize best-in-class technologies that deliver significant customer value across the biopharma and clinical markets," commented Mr. Selman. "The combination of our technologies, R&D strength, global sales network, dedicated teams and commitment to innovation will advance our collective ability to support customer workflows within various stages of drug development and bioprocessing and…
PR Newswire
19/03/2025
CUT AND RUN: The European Society of Plastic, Reconstructive and Aesthetic…
The survey, which spans Europe and the United States, quizzed seven current and past leaders of international surgical societies on the challenges, opportunities, and structural changes needed to address the influence of Gen Z. It revealed that Gen Z are spearheading reduced working hours, enhanced work-life balance, and a decline in hierarchical mentorship with a move towards a more egalitarian and less formal relationship with superiors and peers. A change in working patterns, in particular…
PR Newswire
19/03/2025
Implantica announces further expansion of RefluxStop™ centers of excellence and…
Dr. Peter Forsell, inventor of RefluxStop™, CEO and founder of Implantica, says, "We are pleased to see Dr. Barrasa and his team's drive to advance outcomes for their GERD patients. As the proportion of patients with GERD increases across all age groups¹, more patients are actively seeking surgical treatment, as long-term PPI use is shown to have serious side-effects. The Hospital Vithas 9 de Octubre is among the leaders in innovative GERD treatment, and we are proud to be associated with…
PR Newswire
19/03/2025
Sobi announces a new research collaboration on the development of Gamifant®…
The EMBRACE phase 2a trial (NCT06694701) was approved in March 2025. The first trial sites have been initiated, and patient screening to identify eligible patients with IDS has started. The EMBRACE phase 2a trial ( NCT06694701 ) was approved inMarch 2025. The first trial sites have been initiated, and patient screening to identify eligible patients with IDS has started. The trial design is to be presented at ISICEM by Prof. Evangelos Giamarellos-Bourboulis, MD, PhD, FISAC, principal...
PR Newswire
19/03/2025
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler…
Press ReleaseNicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Results expected in May 2025 Last patient in the U.S. in the ongoing NCX 470 Denali Phase 3 trial has also completed their last visit and results remain on track for Q3 2025March 19, 2025 – release at 7:30 am CETSophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the...
Nasdaq GlobeNewswire
19/03/2025
ONWARD Medical Schedules Reporting of Full Year 2024 Financial Results and…
The webcast will be held on April 1, 2025, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Marver, who will discuss highlights from 2024 and provide a business update.To join the webcast via Zoom, please register using thislink.Participants may also join by phone:+32 2 290 9360 (Belgium)+33 1 7095 0350 (France)+49 69 3807 9884 (Germany)+31 20 794 0854 (Netherlands)+41 22 591 0156 (Switzerland)+44 203 481 5240 (United Kingdom)+1 346 248 7799 (US)…
Nasdaq GlobeNewswire
19/03/2025
Ipsen announces issuance of €500 million inaugural Rated Public Bond
Transaction follows Investment Grade ratings assignment from both S&P and Moody'sPARIS, FRANCE, 19 March 2025 -Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today announced the successful completion of its inaugural Rated Public Bond of €500 million with a coupon of 3.875%, maturing in March 2032.Following the disclosure of the Investment Grade ratings with BBB- from S&P and Baa3 from Moody's, both with a stable outlook, this transaction...
Nasdaq GlobeNewswire
19/03/2025
Primo Partners with ABX to Bring PB01 Closer to Taiwan's Prostate Cancer Market
Data from Taiwan Cancer Registry indicate a steady increase in both, the incidence and mortality of prostate cancer, in recent years [1], underscoring the urgent demand for more accurate diagnostic tools. Radelumin, an innovative diagnostic radiotracer tailored specifically for prostate cancer patients, has already gained approval in France and multiple European countries [2]. Using advanced PET/CT imaging technology, Radelumin and its equivalent for the Taiwanese market, PB01, enable...
Nasdaq GlobeNewswire
19/03/2025
ACG to Host Exclusive Seminar on the Future of Pharmaceuticals and…
These sessions will provide valuable perspectives on the latest market developments, sustainable packaging solutions, and process innovations that are transforming the industry. These sessions will provide valuable perspectives on the latest market developments, sustainable packaging solutions, and process innovations that are transforming the industry. Registration Now Open Attendees are invited to register for the event atEvent Registration. The seminar will serve as an...
PR Newswire
19/03/2025
EMPAVELI's Market Success Underscores Growing Demand for Complement Inhibitor…
Apellis Pharmaceutical's EMPAVELI (pegcetacoplan) Overview Apellis Pharmaceutical's EMPAVELI (pegcetacoplan) Overview EMPAVELI (pegcetacoplan) is a targeted inhibitor of C3 designed to control excessive complement activation—a key immune process that can contribute to the development and progression of serious diseases. Pegcetacoplan binds to complement protein C3 and its activation fragment C3b, helping to regulate the cleavage of C3 and the production of downstream effectors involved...
PR Newswire
18/03/2025
DarwinHealth Recognized and Honored as One of the Top 10 Most Innovative Biotech…
To rank honorees from among thousands of submissions, and using the benchmarks of excellence, forward-thinking, and creativity as its vetting polestar, Fast Company's editors and writers reviewed companies driving progress around the world through a highly competitive application process. The result is a globe-spanning guide to innovation today, from early-stage startups to some of the most valuable companies in the world. On March 18, 2025, DarwinHealth joined the ranks of such biotech…
PR Newswire
18/03/2025
Multiple Myeloma Market to Witness Substantial Growth -- Key Trends and…
The treatment landscape for multiple myeloma is rapidly evolving, particularly with the increasing use of monoclonal antibodies in newly diagnosed patients. DARZALEX has established a strong market position compared to its competitors. Many emerging therapies under evaluation are expected to complement DARZALEX rather than compete directly with it. Johnson & Johnson is actively exploring treatment sequences that combine DARZALEX with TECVAYLI, CARVYKTI, and TALVEY. The treatment landscape…
PR Newswire
18/03/2025
Moon Surgical receives FDA clearance for ScoPilot™ on Maestro, industry's first…
"ScoPilot empowers surgeons to control three instruments with just two hands, while offering a stable, constantly optimal, and safe field of view that is crucial during surgery," said Anne Osdoit, CEO of Moon Surgical, and a Partner at Sofinnova Partners' MedTech accelerator, MD Start. "The control provided by Maestro's ScoPilot will enhance OR efficiency by making the surgeon more autonomous while improving procedural visualization." "ScoPilot empowers surgeons to…
PR Newswire
18/03/2025
K-AI: The First Global Health Integrated Ecosystem Powered by Artificial…
K-AI is not just a project; it is a transformative vision that redefines the future of healthcare by placing AI at the core of health services worldwide. K-AI is not just a project; it is a transformative vision that redefines the future of healthcare by placing AI at the core of health services worldwide. K-AI seeks to revolutionize how healthcare is accessed and managed, combining clinical expertise with the power of AI to enhance decision-making, personalize treatments, and increase...
PR Newswire
18/03/2025
BioAegis Therapeutics to Highlight Lead Product Gelsolin's Critical Role in…
Phase 2 clinical trial will be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium on March 19, 2025.COO Valerie Ceva will present at MedInvest Biotech & Pharma Investor Conference in NYC on March 27, 2025.NORTH BRUNSWICK, N.J., March18, 2025(GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its top...
Nasdaq GlobeNewswire
18/03/2025
DUOncoTM Bone : First CE marked IA algorithm for automatic detection of bone…
DUOnco TMBone : First CE marked IA algorithm for automatic detection of bone lesions on CT scanThe first CE-marked IA for the detection of bones lesionsA world premier : an innovate solution expected of the entire medical professionEnhancement of DUOnco TM, IA range for integration into medical imaging systems Montpellier, France, march 18, 2025. Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and...
Nasdaq GlobeNewswire
18/03/2025
CROSSJECT achieves key ZEPIZURE® manufacturing batch stability milestones
Press ReleaseCROSSJECT achieves key ZEPIZURE ® manufacturing batch stability milestones Satisfactory 6-month room temperature stability results for theRegistration Batchof ZEPIZURE®;CDMO Partner EUROFINS in the process of producing additional validation batches as part of regulatory application;Manufacturing progress supports timelines toward filing of Emergency Use Authorization application by BARDA. Dijon, France March 18, 2025CROSSJECT(ISIN:...
Nasdaq GlobeNewswire
18/03/2025
US Healthcare/Hospital Food Services Market worth US$33.57 billion in 2029 with…
Browse in-depth TOC on "US Healthcare/Hospital Food Services Market" Browse in-depth TOC on "US Healthcare/Hospital Food Services Market" 59 - Tables 46 - Figures 145 - Pages Patient & Dining Services segment,the patient & dining services setting segment is the largest in the US healthcare/hospital food service market, because of their prime position in patient care, satisfaction, and recovery. Hospitals are focusing more on the quality, personalized meal service...
PR Newswire
18/03/2025
Therapeutic Apheresis Market to Reach $2.8 Billion, Globally, by 2035 at 6.7%…
Request Sample of the Report on Global Therapeutic Apheresis Market 2035 - https://www.alliedmarketresearch.com/request-sample/A281407 Request Sample of the Report on Global Therapeutic Apheresis Market 2035 -https://www.alliedmarketresearch.com/request-sample/A281407 Prime determinants of growth The growth of the therapeutic apheresis market is driven by rise in prevalence of chronic and autoimmune diseases, technological advancements in apheresis devices, and favorable...
PR Newswire
18/03/2025
Central Lab Services Market worth US$8.18 billion by 2030with 6.5% CAGR |…
Browse in-depth TOC on "Central Lab Services Market"317 - Tables47 - Figures310 - Pages Browse in-depth TOC on "Central Lab Services Market" 317 - Tables 47 - Figures 310 - Pages By Based on phase,the clinical trial lab services market is divided into phase I, phase II, phase III, and phase IV. Among these, phase III holds the largest market share in 2024 due to the diverse representation in the clinical trials that will ensure treatments effective to different…
PR Newswire
18/03/2025
Healthcare Virtual Assistant Market to Reach $6248 Million by 2031, Driven by AI…
Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-4S2912/Global_Healthcare_Virtual_Assistants_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-4S2912/Global_Healthcare_Virtual_Assistants_Market Major Factors Driving the Growth of Healthcare Virtual Assistant Market: The Healthcare Virtual Assistants Market continues to evolve, supported by cost optimization efforts, patient-centered approaches, and regulatory...
PR Newswire
18/03/2025
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New…
With 800 healthcare institutions across 72 countries regularly contributing their data and expertise to SOPHiA DDM™, the Platform has become one of the most comprehensive sources of real-world intelligence in precision medicine. SOPHiA DDM™ analyzes thousands of new oncology and rare disease cases daily, continuously refining and improving its AI capabilities. Unlike AI models trained in controlled environments, SOPHiA GENETICS's technology is uniquely shaped by real-world data, ensuring its…
PR Newswire
18/03/2025
ASUS Unveils First-Ever Zenbook Ceraluminum Signature Edition at Milan Design…
Ceraluminum™- Inspired by Nature, Engineered for a Sustainable Future Ceraluminum™- Inspired by Nature, Engineered for a Sustainable Future At the core of this collection is ASUS' patented Ceraluminum™ technology—a revolutionary material that redefines durability and sustainability. Used in both the Zenbook S series and Zenbook A14, Ceraluminum™ combines the lightness of aluminum with the resilience of ceramic. The process involves ceramizing aluminum, resulting in a lighter material...
PR Newswire
18/03/2025
Leading Academic and Manufacturing Organizations Join Ori Biotech's Preferred…
Preferred Partner Network (PPN) members will become Centers of Excellence for the IRO ®platform combining best-in-class technology with industry-leading development and manufacturing capabilities.PHILADELPHIA and LONDON, United Kingdom, March18, 2025(GLOBE NEWSWIRE) --Oribiotech Ltd.(Ori), a leader in cell and gene therapy (CGT) manufacturing technology, today announced the launch of its Preferred Partner Network (PPN), bringing together top academic medical centers (AMCs) and...
Nasdaq GlobeNewswire
18/03/2025
Altri Comunicati
